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To assess abnormalities of right heart function and their
reversal with thrombolysis in pulmonary embolism, se-
rial imaging and Doppler echocardiographic studies were
performed before and after a 6 hour intravenous infusion
of 80 to 90 mg of recombinant tissue-type plasminogen
activator (rt-Pa) in seven patients with segmental or
lobar acute pulmonary embolism. None of the five men
and two women had known prior pulmonary hyperten-
sion. Substantial clot lysis and improvement in pulmo-
nary blood flow, as determined by serial pulmonary an-
giography and perfusion lung scanning, were achieved
in all.
Coincident with clot lysis, pulmonary artery systolic
pressure decreased (from 42 ± 11 to 26 ± 7 mm Hg,
p < 0.005), right ventricular diameter decreased (from
3.9 ± 1.0 to 2.0 ± 0.5 em, p < 0.005) and left ven-
tricular diameter increased (from 3.7 ± 0.9 to 4.4 ±
0.6 em, p < 0.01). Right ventricular wall movement,
initially mildly, moderately or severely hypokinetic in
Pulmonary embolism can be a catastrophic event, resulting
in early death or serious hemodynamic dysfunction (1-4).
Sudden increases in pulmonary artery pressure, especially
in patients without prior chronic heart or lung disease re-
sulting in progressive right ventricular hypertrophy, may
cause right ventricular failure and hypotension (1,2). Pre-
vious echocardiographic studies (5-13) have detailed certain
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one, two and four patients, respectively, normalized in
five and improved to mild hypokinesia in two. Tricuspid
regurgitation was present before lytic therapy in six pa-
tients. In five, flow velocity in the tricuspid regurgitant
jets indicated a peak systolic right ventricular minus
right atrial pressure gradient of 25 to 52 mm Hg. Tri-
cuspid regurgitation was detected early after lytic ther-
apy in only two patients. Systolic septal flattening was
noted before but not after lysis.
These findings confirm that pulmonary emboli may
result in appreciable right ventricular dysfunction and
dilation, resultant tricuspid regurgitation, abnormal septal
position and decreased left ventricular size. Their early
reversal after rt-PA suggests that this therapy might be
efficacious in the management of patients with pulmo-
nary embolism presenting with more serious hemody-
namic compromise. The potential of rt -PAin this regard
merits further investigation.
() Am Colt Cardiol 1987;10:971-8)
changes that may be seen in pulmonary embolism, namely,
thrombi within the right heart chambers or pulmonary artery,
right ventricular dilation, right ventricular hypokinesia, ab-
normalities of septal movement, reduced left ventricular
cavity dimension and dilation of the pulmonary artery. The
cited studies generally did not address whether detected
abnormalities diminished over time, except to state that
detected thrombi often disappeared on follow-up study
(5,8,10,12). Nicolosi et al. (7), however, observed de-
creases in right ventricular size, increases in left ventricular
size and changes in septal curvature in follow-up studies.
This study was designed to determine prospectively the
presence and magnitude of right ventricular dysfunction,
using imaging and Doppler echocardiography, in consec-
utive patients with symptomatic, angiographically docu-
mented acute pulmonary embolism who met the criteria for
inclusion in an ongoing trial of experimental thrombolytic
0735-1097/X7/$3.50
972 COME ET AL.
VENTRICULAR DYSFUNCTION IN PULMONARY EMBOLISM
lACC Vol. 10, NO.5
November 1987:971-8
therapy. Our major objective was to determine whether de-
tected abnormalities of cardiac function are rapidly reversed
after intravenous administration of recombinant tissue-type
plasminogen activator (rt-PA), a relatively fibrin-specific
thrombolytic agent that results in significant and marked
improvement in pulmonary artery patency as early as 2 to
6 hours after the start of infusion (14).
Methods
Study patients. Eight consecutive patients undergoing
pulmonary angiography and experimental recombinant tis-
sue-type plasminogen activator (rt-PA) therapy for angio-
graphically confirmed pulmonary embolism were consid-
ered for serial echocardiographic evaluation of right ventricular
function. One patient was excluded because the echocar-
diographic equipment was not available before administra-
tion of lytic therapy. To be included in the study, patients
had to be 18 years of age or older, with angiographic doc-
umentation of pulmonary embolism in segmental or more
proximal pulmonary artery branches. Lytic therapy had to
be administered within 5 days of the onset of symptoms,
and patients with prior pulmonary embolism were ineligible.
Written consent was obtained from all patients, according
to a protocol approved by the Human Subjects Committee
of the Beth Israel Hospital and by the U.S. Food and Drug
Administration.
Echocardiographic evaluation. M-mode, two-dimen-
sional and pulsed Doppler echocardiographic studies were
performed using an ATL Mark 600 echocardiograph. Two-
dimensional scans were obtained in parasternal long- and
short-axis planes, apical two and four chamber planes and
the subcostal four chamber plane. Right ventricular wall
movement was graded as normal or as mildly, moderately
or severely hypokinetic on the basis of analysis of right
ventricular wall movement in the combination of paraster-
nal, apical and subcostal views. M-mode echocardiograms
were generated using a two-dimensionally-directed cursor
from the left ventricle at the upper chordal level, with the
patient in the supine position. M-mode tracings were taken
from the parasternal long-axis view (six patients) or from
the subcostal four chamber view (one patient in whom the
parasternal view was technically difficult). Right ventricular
dimension was measured from the leading edge of the right
ventricular wall to the leading edge of the right septal surface
at the onset of the QRS complex (15). Right ventricular
wall thickness was measured from the leading edge of the
right side of the right ventricular wall to the leading edge
of its left side. Left ventricular diastolic diameters at the
upper chordal level were measured from the leading edge
of the left septal surface to the leading edge of the posterior
wall at the onset of the QRS complex (15).
Pulsed Doppler echocardiography including, when nec-
essary, high pulsed repetition frequency technology was
used to determine the presence of tricuspid regurgitation and
to quantitate its flow velocity. Using short-axis, right ven-
tricular inflow tract and apical four chamber views, the
sample volume was positioned on the atrial side of the
tricuspid valve. Holosystolic turbulence was considered in-
dicative of tricuspid regurgitation. Maximal flow velocity
in the tricuspid regurgitant jet was measured, and the right
ventricular (RY) to right atrial (RA) pressure gradient was
determined according to the modified Bernoulli equation
(16): (RY pressure - RA pressure [in mm Hg]) == 4 v:
where Y == maximal flow velocity in the tricuspid regur-
gitant jet.
The imaging and Doppler echocardiographic studies were
performed a mean of 10 hours (range 0 to 14) before admin-
istration of intravenous rt-PA and a mean of 9 hours (range
oto 36) after completion of therapy.
Catheterization technique and drug administration.
An 8F Grollman catheter was placed, using the Seldinger
technique, through the femoral vein into the right heart
chambers and pulmonary artery. Right atrial, right ventric-
ular and pulmonary artery pressures were recorded using
Hewlett-Packard transducers (l295A) and a Hewlett-Pack-
ard monitoring system (78353A). Systemic arterial pressure
was measured using a cuff sphygmomanometer rather than
an indwelling arterial catheter to avoid a potential site for
bleeding with subsequent thrombolytic therapy. Selective
pulmonary angiograms were performed, with the side of
injection (right or left pulmonary artery) generally chosen
according to which lung on perfusion scanning had the greater
number of defects. After diagnosis of thrombus in a seg-
mental or more proximal pulmonary artery branch, 50 mg
of rt-PA (Activase, Genentech, Inc.) was infused intrave-
nously for 2 hours at a rate of 25 mg/h. Selective pulmonary
angiography was repeated at the end of the 2 hour infusion.
If significant thrombus or thrombi remained, an additional
40 mg of rt-PA was infused intravenously over the next 4
hours at a rate of 10 mg/hour, unless precluded by bleeding
complications such as an expanding groin hematoma. Total
doses of rt-PA given to the seven patients in this study were
85 ± 5 mg. At the end of the 6 hour total infusion, selective
pulmonary angiograms were repeated. The total amount of
contrast medium (diatrizoate meglumine) used was 30 to 40
cc for each of the three angiographic evaluations.
Analysis of pulmonary angiograms. The pulmonary
angiograms were coded, scrambled as to whether they were
pretreatment, 2 hour or 6 hour films, and read without
knowledge of patient data by a panel of six investigators.
The scoring system used for analysis of the single lung
angiogram was similar to the one employed in the Urokinase
Pulmonary Embolism Trial (17) for assessment of both lungs,
and has been described previously (14). The unilateral lung
angiograms were graded from 0 (no clot) to 9 (massive clot).
Medium-sized emboli were given a score of <3 and gen-
erally involved one lobe. Large emboli were given a score
lACC Vol. 10, No 5
November 1987:971-8
COME ET AL.
VENTRICULAR DYSFUNCTION IN PULMONARY EMBOLISM
973
Figure 1. Patient 4. Selective leftpul-
monary angiograms before (leftpanel)
andafter(right panel) a 6 hourintra-
venous infusion of recombinant tissue-
type plasminogen activator (rt-PA). A
large embolus is seen in the left main
pulmonary artery (large whitearrow)
and smaller emboli are seen to par-
tially occlude its branches (smaller
white arrows). After the 6 hour in-
fusion, visible thromboemboli have
almost completely disappeared, and
anterograde flow isnow evident inmost
of the vessels previously blocked by
clot. The pulmonary angiographic score
decreased from 8.7 to 1.7 ± 0.8.
of 3 to 6 and generally involved two lobes. Massive emboli
were given a score of 7 to 9 and involved the entire lung.
Qualitatively, all seven patients had angiographic evidence
for almost complete lysis of pulmonary artery thrombi after
therapy (Fig. I).
Perfusion lung scanning technique and scoring sys-
tems. Perfusion lung scans were performed in anterior,
posterior, right and left anterior oblique, right and left pos-
terior oblique projections after injection of 2 MBq of tech-
netium-99m macroaggregated albumin into an antecubital
vein. Defects on the perfusion lung scan were graded by
two observers who were unaware of the sequence of pre-
and post-therapy scans, using both an anterior/posterior view
scanning method similar to the method reported in the Uro-
kinase Pulmonary Embolism Trial (17) and a method based
on segmental anatomy that scored all of the views obtained
during the perfusion scan (18).
Statistical analysis. Data are presented as mean ± stan-
dard deviation. Comparisons of variables before and after
peripheral venous infusion ofrt-PA therapy were performed
using the Student's paired t test; probability (p) values of
<0.05 were considered significant.
Results
Clinical features. The study included five men and two
women with a mean age of 58 years (range 44 to 71). No
patient had known underlying chronic pulmonary hyperten-
sion, and mean right ventricular wall thickness by echo-
cardiographic study was normal (4.7 mm; range 2 to 6).
Underlying diseases or conditions predisposing to pulmo-
nary embolism were present in four of the seven patients
and included ovarian and prostatic carcinoma in one each,
recent ankle fracture with subsequent orthopedic surgery in
one patient and repeated endomyocardial biopsies in one
patient who had undergone cardiac transplantation (Patient
I in Tables I to 4). Presenting symptoms for pulmonary
embolism included the following: dyspnea in all seven pa-
tients, pleuritic or other chest pain in five, near syncope in
three and hemoptysis in one.
The diagnosis was first suspected by one of the patient's
primary physicians in six of the seven patients. The other
patient (Patient 4) was referred to the echocardiographic
laboratory for suspected pericardial disease because of
symptoms of shortness of breath and near syncope. The
diagnosis was first suspected from echocardiographic find-
ings of right ventricular dilation and hypokinesia and tri-
cuspid regurgitation with an estimated systolic right ven-
tricular to right atrial pressure gradient of 27 mm Hg in the
absence of identifiable left heart disease.
Presenting physical signs, recorded by the admitting phy-
sician, included a heart rate 2: 100 beats/min in six patients,
jugular venous distension (estimated jugular venous pressure
>8 em H20 ) in four patients and accentuation of the pul-
monary component of the second heart sound in two pa-
tients. The baseline chest X-ray film was officially read as
abnormal in three of the patients, showing a parenchymal
infiltrate in three and a pleural effusion in one of these.
The electrocardiogram revealed a normal sinus mecha-
nism in all patients, an axis of 2: 100° in none of the patients,
an S!,Q3,T3 pattern in three patients and inversion of the T
waves in the right precordial or inferior leads, or both, in
two patients. Arterial blood gas determinations revealed a
partial pressure of oxygen (P02) on room air of less than
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Table 1. Hemodynamic Findings in Seven Patients
Heart Rate PA Systolic Pressure RA Pressure Systemic Arterial
(beats/min) (mm Hg) (mm Hg) Pressure (mm Hgj PA/SAP
Patient No. Pre Post Pre Post Pre Post Pre Post Pre Post
1 92 97 37 19 4 2 120 120 0.31 0.16
2 78 80 38 32 7 5 118 130 0.32 0.25
3 80 84 34 23 2 2 132 114 0.26 0.20
4 97 82 54 28 19 12 130 160 0.42 0.18
5 92 72 49 38 10 8 132 114 0.37 0.33
6 107 95 29 20 2 102 145 0.28 0.14
7 92 92 56 22 5 2 112 104 0.50 0.21
Mean ±SD 91 ± 10 86 ± 9 42 ± II 26 ± 7* 7 ± 6 5 ± 4t 121 ± II 127 ± 20 0.35 ± 0.08 0.21 ± 0.06*
*p < 0.01, pre vs. post; tp < 0.05, pre vs. post. BP = blood pressure; HR = heart rate; PA = pulmonary artery; PA/SAP = ratio ofpulmonary
artery systolic pressure to systemic arterial systolic pressure; Post and Pre = after and before thrombolytic therapy, respectively; RA = right atrial.
80 torr in five of the six patients whose blood gases were
assessed.
Several patients had minor. easily controlled bleeding
from venipuncture and prior radial arterial (for blood gas
analysis) sites during or early after rt-PA infusion. The only
major complication was hemorrhage into an ovarian car-
cinoma in Patient 6, occurring several hours after rt-PA
infusion and necessitating exploratory laparotomy and re-
moval of the previously undiagnosed pelvic mass.
Hemodynamic findings (Table 1). Administration of
recombinant tissue-type plasminogen activator (rt-PA) was
associated with significant reductions in pulmonary artery
systolic pressure (from 42 ± 11 to 26 ± 7 mm Hg, p <
0.01) and right atrial pressure (from 7 ± 6 to 5 ± 4 mm
Hg, p < 0.05). The ratio of systolic pulmonary artery pres-
sure to systolic systemic arterial pressure decreased from
0.35 ± 0.08 to 0.21 ± 0.06 (p < 0.01).
Pulmonary angiographic findings (Table 2, Fig. 1).
Significant improvement in pulmonary angiographic scores
was noted at both 2 hours (p < 0.01) and 6 hours (p <
0.001) after the start of rt-PA infusion, and repeat lung
perfusion scans at 24 hours demonstrated significant in-
creases in pulmonary blood flow (p < 0.0001 and p <
Table 2. Pulmonary Angiographic Scores in Seven Patients
Patient 2 Hours 6 Hours
No. Pre Post Post
1 7.8 7.5 5.5
2 8.8 8.4 1.2
3 8.3 6.8 3.3
4 8.7 7.5 1.7
5 5.7 4.0 1.2
6 8.5 5.8 2.8
7 8.7 6.0 4.0
Mean 8.1 6.6 2.8
± SO 1.1 1.5* 1.6t
*p < 0.01, 2 hours post vs pre; tp < 0.001, 6 hours post vs pre. Post
and Pre = after and before thrombolytic therapy, respectively.
0.005 using the segmental and UPET scoring methods, re-
spectively).
Perfusion lung scan findings (Table 3, Fig. 2). The
mean time between infusion of thrombolytic therapy and
the post-therapy lung scans was 25.2 ± 3.8 hours. All seven
patients demonstrated improvement in the perfusion lung
scan after rt-PA. The initial score, based on the method of
the Urokinase Pulmonary Embolism Trial (17), improved
65 ± 18% from 0.45 ± 0.21 to 0.16 ± 0.11 (p < 0.005).
The initial score, based on the segmental method, improved
62 ± 8% from 0.49 ± 0.19 to 0.18 ± 0.08 (p < 0.001).
Echocardiographic findings (Table 4, Fig. 3 and 4).
There were marked changes in imaging and Doppler echo-
cardiographic variables after rt-PA infusion. Right ventric-
ular diameter decreased significantly (3.9 ± 1.0 to 2.0 ±
0.5 ern, p < 0.005), and left ventricular diameter increased
(3.7 ± 0.9 to 4.4 ± 0.6 em, p < 0.01). Right ventricular
wall movement, initially graded as mildly, moderately or
severely hypokinetic in one, two and four patients, respec-
tively, normalized in five patients and improved to mild
hypokinesia in the other two. Six patients had Doppler-
detectable tricuspid regurgitation before rt-PA. In five of
these, flow velocities were increased, compatible with mild
to moderate elevation of right ventricular systolic pressure.
Mean peak systolic right ventricular minus right atrial pres-
sure gradient, estimated from the tricuspid regurgitant jets
in these five patients, was 34 mm Hg. Tricuspid regurgi-
tation was detected after completion of lytic therapy in only
two patients and had disappeared at restudy 5 days later in
one of them. Systolic septal flattening, evident before rt-
PA infusion in four of the six patients with adequate short-
axis images, was observed in none of the patients after lysis.
Discussion
Study findings. We have demonstrated that intravenous
infusion of recombinant tissue-type plasminogen activator
(rt-PA) is associated with significant and early reversal of
JACC Vol. 10, No.5
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Table 3. Lung Scan Scores in Seven Patients
Segmental Method Ul'E'l MethodPatient
No. Pre Post Pre Post
0.40 o 17 0..17 0.19
2 0.41 0.20 O.4h 0.29
3 0.31 0.09 o 12 0.04
4 0.32 0.14 (U7 0.05
5 0.51 o 13 0.46 0.0.1
h O.hX 022 05h 0.25
7 (l.XI (U2 OXO 0.25
Mean 0.49 o IX 0.45 0.16
±SD 0.[9 O.OH' 0.21 0.111"
*p < 0.005, post vs. pre: I"p < 0.001. Post vs. Pre. Post and Pre c; after and hefore thrombolytic therapy,
respectively: UPET = Urokinase Pulmonary Embolism Trial.
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right ventricular dilation and hypokinesia, tricuspid regur-
gitation and decreased left ventricular cavity dimension.
These changes occur with decreases in pulmonary artery
Figure 2. Patient 4, Perfusion lung scans inanterior (ANT), pos-
terior (POST), right anterior oblique (RAO), left anterior oblique
(LAO), right posterior oblique (RPO) and left posterior oblique
(LPO) projections before (top panels) and after (bottom panels)
recombinant tissue-type plasminogen activator (rt-PA) infusion,
Multiple segmental areas of absent or reduced perfusion are seen
on the first study. The study performed after lytic therapy reveals
much more homogeneous lung uptake, with only small residual
perfusion defects. By the Urokinase Pulmonary Embolism Trial
(17) lung scan scoring method, this patient had an 86% improve-
ment inscore from 0.37 to0.05. Bythesegmental scoring system,
there was a 56% improvement, with the score decreasing from
0,32 before to 0,14 after rt-PA infusion.
pressure and with evidence of reperfusion on angiographic
study, This study is the first to show reversal of imaging
and Doppler echocardiographic abnormalities after throm-
bolytic therapy. The early reversal of the detected abnor-
malities suggests that the right ventricle is not "stunned."
but rather is capable of recovering quickly in response to a
decrease in right ventricular afterload.
Pathophysiology of acute pulmonary embolism. The
right ventricle of an individual without prior heart or lung
disease cannot generate mean pulmonary artery pressures
higher than 30 to 40 mm Hg, presumably because of the
absence of right ventricular hypertrophy (I), With progres-
sive increases in pulmonary vascular resistance. therefore,
the right ventricle begins to fail, resulting in elevation of
right atrial pressure and symptoms and signs of right heart
failure (I), There is a significant relation between mean
pulmonary artery pressure and mean right atrial pressure
( I), Stroke volume and. consequently. cardiac output may
be maintained in some patients on the basis of increased
sympathetic drive and the Frank-Starling mechanism, In
others, generally those with massive embolism. failure to
maintain stroke volume may result in a decreased cardiac
output, cardiogenic shock and death, In patients with prior
heart or lung disease, or both, right ventricular hypertrophy
usually permits generation of higher pulmonary artery pres-
sures (19), In such patients with antecedent pulmonary hy-
pertension, there is no relation between right ventricular
dysfunction and the extent of angiographic obstruction (2),
Mortality is increased in patients with pulmonary embolism
who have obvious impairment of right ventricular func-
tion (2),
Most clinical studies likely have underestimated the prev-
alence and severity of hemodynamic disturbances resulting
from symptomatic pulmonary embolism. because they have
included patients surviving long enough to be evaluated and
enrolled in study protocols. Mortality is very high and occurs
early in patients presenting with major hemodynamic com-
promise. Studies (3,4) have documented that 50. 70 and
85% of such patients die within 30 minutes. I hour and 6
hours. respectively,
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Table 4. Imaging and Doppler Echocardiographic Findings in Seven Patients
~-------
RV Diameter l.V Diameter
(UII) (ern) TRPatient -_._--
-----
No. Pre Pnst Pre Post Pre Post
-_.._-- ----~_.-----.__ ._-- ,_._~-- ----
.L2 2.5 39 47 +
2 .1.2 2.0 53 5.5 +
3 3.7 1.7 4.0 4.5
4 60 2.4 3.1 42 +
5 39 20 2.9 4.2 +
f> 3f> I.K .1.0 3.7 +
7 3.6 I 2 .1.1 4.2 + +
Mean 3.9 2.0 37 4.4






























'p < 0.005. Post vs. Pre: tp < 001. Post vs. Pre. LV '" left ventricular; Post and Pre > after and before thrombolytic therapy. respectively; RA
'" right atrial: RV = right ventricular; sys '" systolic; TR = tricuspid regurgitation .
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Figure 3. Patient 4. M-mode echo-
cardiograms obtained using a subcos-
tal approach before (left panel) and
after (right panel) thrombolytic ther-
apy demonstrate a marked decrease in
the diameter of the right ventricle (RV)
from 6.0 to 2.35 em, and an increase
in the diameter of the left ventricle
(LV) from 3.1 to 4.2 em. Right ven-
tricular wall movement, which was
markedly hypokinetic during acute
pulmonary embolism, improved ap-
preciably after lytic therapy. EKG =
electrocardiogram; PW = posterior
wall; SEP = septum; TV = tricuspid
valve.
Figure 4. Patient 4. Subcostal two-
dimensional images at end-diastole
corresponding to the M-mode tracings
shown in Figure 3. Before recombi-
nant tissue-type plasminogen activator
(rt-PA) therapy (left panel), the right
ventricle (RV) is markedly enlarged
and left ventricular (LV) diameter is
reduced. The study performed after in-
fusion of rt-PA (right panel) shows a
remarkable decrease in right ventric-
ular size and a corresponding increase
in the size of the left ventricle. RA =
right atrium; other abbreviations as in
Figure 3.
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Treatment of acute pulmonary embolism. Conven-
tional therapy for acute pulmonary embolism has been the
administrationof intravenous heparin. Although heparin has
been shown experimentally to prevent recurrences of pul-
monary emboli (20) and progression of thrombus format ion
in areas of pulmonary artery embolism (21), it produces no
major change in the extent of pulmonary perfusion abnor-
malities, assessed by lung scan, or in the magnitude of
pulmonary artery pressure, right atrial pressure and total
pulmonary vascular resistance elevation when measure-
ments are repeated 24 hours afterthe start of therapy (17,22).
In contrast, thrombolytic therapy with streptokinase or uro-
kinase has been associated with a significant reduction in
the extent of angiographic obstruction, perfusion abnor-
malities and elevations of pulmonary artery pressure, right
heart pressuresand total pulmonary resistance 24 hoursafter
the start of infusion (17,22,23). Recent reports (14,24) have
also documented the efficacy of rt-PA, a relatively clot-
specific fibrinolytic agent. In a study of 30 patients with
angiographically proved pulmonary embolism presenting
within 5 days of the onset of symptoms, Goldhaber et al.
(14) found significant angiographic evidence of clot lysis
and significant decreases in pulmonary artery pressure 6
hours after the start of 2 to 6 hour intravenous infusions of
rt-PA.
The favorable angiographic, perfusion lung scan and
echocardiographic changes observed after administration of
thrombolytic agents inour patients suggest that such therapy
might be effective in decreasing mortality in that subgroup
of patients with massive embolism who survive long enough
to have the diagnosis considered. Certainly, thrombolytic
therapy can be instituted more rapidly in hemodynamically
unstable patients than can open embolectomy on cardio-
pulmonary bypass, a procedure that has been successful in
saving some patients with hemodynamic decompensation
butcarries an operative mortality rate of 24 to 93% (25-27 ).
Transvenous catheter embolectomy can be undertaken more
quickly than can open surgical embolectomy. Although suc-
cessful thrombectomy may produce improvement in car-
diovascular function in some patients, mortality remains
high (25) and the procedure requires the availability of a
catheterization laboratory. Our study did not address the
potential for rt-PA therapy to improve cardiovascular func-
tion or survival in patients with pulmonary embolism with
prior cardiac or pulmonary disease or with shock resulting
from acute pulmonaryembolism. The efficacy of rt-PA ther-
apy in such patients merits investigation.
Most pulmonary emboli probably undergo endogenous
lysis over a numberof days, accounting for the observations
in the Urokinase Pulmonary Embolism Trial (17) that mean
lung scan improvement by 7 days was equivalent in the
heparin-treated and the urokinase/heparin-treated groups. In
some patients, however, pulmonary emboli persist and be-
come organized, and the resultantchanges may be the cause
of a syndrome of unresolved pulmonary emboli character-
ized by symptoms of dyspnea, persistence of perfusion lung
scan abnormalities, mild to moderate pulmonary hyperten-
sion and right ventricular hypertrophy (28- 31). It is not
known whether thrombolytic therapy followed by long-term
anticoagulation will be preferable to anticoagulation alone
in decreasing the incidence of chronic morbidity related to
pulmonary embolism.
Considerations for future studies. Our favorable short-
term results in selected patients without severe cardiac or
respiratory compromise suggest that randomized trials com-
paring thrombolytic therapy with anticoagulant therapy alone
and examining different types of thrombolytic therapy should
be undertaken to determine their relative risks and efficacies
in decreasing mortality from massive pulmonary embolism
and preventing potential syndromes of unresolved pulmo-
nary embolism, chronic hypoxemia and peripheral venous
disease. Such studies should optimally include periodic as-
sessment of right ventricular performance, pulmonary func-
tion and the peripheral venous system in addition to eval-
uation of the acute hemodynamic, angiographic and per-
fusion lung scan changes after therapy.
Appendix
Other participating investigators include
Beth Israel Hospital, Gerald M. Kolodny, MD.
Br igham and Women' s Hospital , B. Leonard Holman . MD; Joseph
Loscalzo, MD, PhD; Michael Meyerovitz, MD; Kathleen Reagan. MD;
Andrew P. Se lwyn. MD; Sabah Turneh; MD; Douglas Vaughan. MD .
Gene nlech , Inc. , Elliott B. Grossbard, MD .
Geor ge Washington Universit y Medical Cenler, Edward Druy, MD:
William Kelly , MD; Craig M. Kessler, MD: K. Siena Kirwin , MD.
Veterans Administration Medical Center at Brockton/West Rox-
bury, Douglas L. Dawley. MD: Daniel A. Pietro . MD; Arthur Sasahara,
MD; G.V.R.K. Sharma, MD.
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